Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
TELIX PHARMACEUTICALS LIMITED (TLX)ASX AI Signals has generated 0 signals for TLX during the last 90 days, indicating low trading activity
TLX Share Price | |
| Current Price | $16.880 |
| 52 Week High | $25.390 |
| 52 Week Low: | $8.630 |
| Trading at (% of 52 Week High) | 66.48% |
Telix Pharmaceuticals Limited (ASX: TLX) is a biopharmaceutical company focused on developing and commercializing diagnostic and therapeutic products using molecularly targeted radiation. The company specializes in treatments for cancer and other serious diseases, aiming to improve patient outcomes through precision medicine. Telix operates globally, with a portfolio that includes imaging agents and radiopharmaceutical therapies.
The Pharmaceuticals, Biotechnology & Life Sciences sector on the ASX includes companies involved in the development, production, and commercialization of drugs, medical devices, and biotechnology products. This sector covers activities such as research and development of new medicines, genetic testing, and innovative healthcare technologies. Companies often work on treatments for diseases, including cancer, infectious diseases, and chronic conditions. The sector plays a crucial role in advancing medical science and improving patient care through innovation.
Telix Pharmaceuticals Limited
FDA and Telix align on advancement into Part 2 of the ProstACT Global Phase 3 study in the United States. FDA agrees with the clinical protocol and proposed statistical framework across three standard-of-care combination cohorts. Part 2 (randomized cohort) continues to Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces an educational webinar exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma) and ho ​Telix Pharmaceuticals Limited (NASDAQ:TLX) is one of the best new stocks to buy with the huge upside potential. On June 2, Telix Pharmaceuticals and United Imaging Healthcare signed an MoU to establish a strategic research collaboration in the US. This partnership aims to advance integrated therano MELBOURNE, Australia and KYOTO, Japan, Nov. 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the official opening of Telix Manufacturing Solutions (TMS) in Yokohama, Japan, the Company's first cyclotron facility in the Asia Pacific region (APAC) The Australian market has recently experienced a boost in sentiment, with the ASX200 up 1.3% and nearly every sector showing gains, driven by positive tech earnings from global giants like NVIDIA. This improvement comes amidst ongoing concerns about potential bubbles in the AI sector and geopoliticaLatest TELIX PHARMACEUTICALS LIMITED(TLX) News
FDA Alignment to Advance ProstACT Global Phase 3 Trial
Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
Telix Pharmaceuticals (TLX), United Imaging Healthcare Form Strategic Theranostics Research Partnership
Telix Opens TMS Yokohama in Japan, Commemorative Lecture Held
ASX Stocks Estimated To Be Up To 35.6% Below Intrinsic Value
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial